Beyond CD19 CAR-T cells in lymphoma

Wingchi K. Leung, Adanma Ayanambakkam, Helen E. Heslop, La Quisa C. Hill

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability of CD19 CAR-T cells is limited to B cell malignancies and antigen loss can result in treatment failure, prompting the exploration of alternative targets to overcome tumor escape via CD19 antigen loss, as well as extend the CAR-T cell platform to treat Hodgkin and T cell lymphomas. This review highlights recent clinical trials testing CAR-T cell targets beyond CD19.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalCurrent Opinion in Immunology
StatePublished - Feb 2022


  • Antigens, CD19/immunology
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma/immunology
  • Neoplasm Recurrence, Local/immunology
  • Receptors, Antigen, T-Cell/genetics
  • Receptors, Chimeric Antigen/genetics
  • T-Lymphocytes/immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Beyond CD19 CAR-T cells in lymphoma'. Together they form a unique fingerprint.

Cite this